Anti-tigit antibodies

An isolated nucleic acid encoding an antibody or antigen binding fragment thereof that binds to human TIGIT, wherein the antibody or antigen binding fragment is selected from the group consisting of:

• a. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:
• 1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 79, 80, 81, 82, 83 or 140, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, 65, 66, 67, 68, 69, 70, 71, 72, 73 or 41, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 74, 75, 76, 77, 78 or 142;
• b. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:60, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:61, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:62;
• and
• c. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:88, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:89, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 134, 135 or 147, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:90, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 or 167, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:91, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 or 148, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:93.

A method of treating cancer in a human subject, comprising administering to the subject an effective amount of an antibody or antigen binding fragment thereof that binds to human TIGIT, wherein the antibody or antigen binding fragment is selected from the group consisting of:

• a. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:
• 1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 79, 80, 81, 82, 83 or 140, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, 65, 66, 67, 68, 69, 70, 71, 72, 73 or 41, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 74, 75, 76, 77, 78 or 142,
• b. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:60, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:61, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:62;
• and
• c. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:88, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:89, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 134, 135 or 147, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:90, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 or 167, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:91, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 or 148, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:93;
• optionally in association with a further therapeutic agent or therapeutic procedure.

A method of treating an infection or infectious disease in a human subject, comprising administering to the subject an effective amount of an antibody or antigen binding fragment thereof that binds to human TIGIT, wherein the antibody or antigen binding fragment is selected from the group consisting of:

• a. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:
• 1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 79, 80, 81, 82, 83 or 140, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, 65, 66, 67, 68, 69, 70, 71, 72, 73 or 41, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 74, 75, 76, 77, 78 or 142;
• b. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:60, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:61, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:62;
• and
• c. an antibody or antigen binding fragment comprising:
• a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:88, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:89, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 134, 135 or 147, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:90, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 or 167, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:91, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:92, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 or 148, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:93;
• optionally in association with a further therapeutic agent or therapeutic procedure.